REGULATORY
Kymriah Up for MHLW Panel Review on Feb. 20 as Japan’s 1st CAR-T Therapy
A key health ministry committee will review Novartis Pharma’s Kymriah (tisagenlecleucel) as Japan’s first CAR-T cell therapy on February 20. If it clears the panel and then wins approval, it will finally set the stage for official debates surrounding the…
To read the full story
Related Article
- Kymriah Pre-Treatment Regimens Up for Review on Feb. 22
February 12, 2019
- MHLW Panel to Discuss Orphan Status for Takeda’s Stem Cell Therapy on Feb. 20
February 7, 2019
REGULATORY
- MHLW Lifts Olanzapine Diabetes Contraindication for Antiemetic Use
August 26, 2026
- PMDA Flags Severe Gastritis, Esophagitis with Checkpoint Inhibitors
August 26, 2026
- Japan Grants Sakigake Tag to NS-035, MSA-01
August 26, 2026
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
August 25, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





